



SESSION REFERENCE: 4-3

TITLE: ONE AND TWO YEARS FOLLOW-UP OF RADIOFREQUENCY SEGMENTAL THERMAL ABLATION (RSTA) OF GREAT SAPHENOUS VEINS (GSVS)

Author(s): (Presenter is underlined):

Thomas M Proebstle and the European CLF-Study Group

Author Affiliation(s):

Dept of Dermatology, University of Pecs, Pecs, Hungary

OBJECTIVE(S):

Radiofrequency segmental thermal ablation has been introduced recently for ablation of incompetent GSVs but mid-term results still have to be reported.

METHOD(S):

N = 295 GSVs in 225 patients were treated by RSTA under local anesthesia in a prospective multicenter trial. Duplex-ultrasound and clinical data were obtained after 3 days, 3, 6, 12 and 24 months.

RESULT(S):

N=292 of 295 treated limbs were followed at one year, 2 year examination was performed on n=31 limbs. During follow-up, one vessel was open at 3 days but occluded thereafter. Full or partial recanalizations were n=1 at 3 months, n=3 at 6 months and n=3 at 1 year after treatment. Corresponding occlusion rates according to life-table analysis were 99.7% at 3 days, 99.3% after 3 months, 98.3% after 6 months and 97.2% after 1 and 2 years. The average VCSS score improved from 3.9 ± 2.1 before treatment to 3.5 ± 1.2 at 3 days, to 0.9 ± 1.5 at 3 months, 0.7 ± 1.2 at 6 months, 0.6 ± 1.3 at 1 year and 0.3 ± 0.5 at 2 years thereafter. Presence of any pain in the treated limb improved from 58.6% before treatment to 48.5%, 33.3%, 12.5%, 3.1% and 0% at the same follow-up intervals. Likewise, presence of leg swelling improved from 52.9% to 6.4%, 8.3%, 8.3%, 4.5% and 0%. Side effects noticed at any time during follow-up in the RSTA-treated area were ecchymosis (5.8%), paresthesia (3.4%), erythema (2.0%), skin pigmentation (2.7%), hematoma (1.4%) and phlebitis (1.0%).

CONCLUSION(S):

RSTA of the GSV shows a high and stable success rate with a moderate side-effect profile and remarkable improvement of clinical symptoms.

DISCLOSURE INFORMATION PROVIDED AT TIME OF ABSTRACT SUBMISSION

Potential Conflict of Interest? Yes

Conflict Details: Thomas M Proebstle, consultant of VNUS Medical

Outside Funding? Yes

Funding Details: study was sponsored by VNUS Medical